These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21993716)

  • 1. Gastric infection by Helicobacter pylori.
    Sachs G; Scott DR; Wen Y
    Curr Gastroenterol Rep; 2011 Dec; 13(6):540-6. PubMed ID: 21993716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric infection by Helicobacter pylori.
    Sachs G; Wen Y; Scott DR
    Curr Gastroenterol Rep; 2009 Dec; 11(6):455-61. PubMed ID: 19903421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The life and death of Helicobacter pylori.
    Scott D; Weeks D; Melchers K; Sachs G
    Gut; 1998 Jul; 43 Suppl 1(Suppl 1):S56-60. PubMed ID: 9764042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.
    Marcus EA; Sachs G; Scott DR
    Aliment Pharmacol Ther; 2015 Oct; 42(7):922-33. PubMed ID: 26238858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Apr; 21(16):5032-8. PubMed ID: 25945019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of systemic eradication therapy against oral Helicobacter pylori.
    Bago I; Bago J; Plečko V; Aurer A; Majstorović K; Budimir A
    J Oral Pathol Med; 2011 May; 40(5):428-32. PubMed ID: 21198868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.
    Mahmoudi L; Farshad S; Seddigh M; Mahmoudi P; Ejtehadi F; Niknam R
    Medicine (Baltimore); 2016 Oct; 95(42):e4410. PubMed ID: 27759625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
    Holtmann G; Layer P; Goebell H
    Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and clinical management of
    de Brito BB; da Silva FAF; Soares AS; Pereira VA; Santos MLC; Sampaio MM; Neves PHM; de Melo FF
    World J Gastroenterol; 2019 Oct; 25(37):5578-5589. PubMed ID: 31602159
    [No Abstract]   [Full Text] [Related]  

  • 10. The gastric biology of Helicobacter pylori.
    Sachs G; Weeks DL; Melchers K; Scott DR
    Annu Rev Physiol; 2003; 65():349-69. PubMed ID: 12471160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current regimens for treatment of Helicobacter pylori infection.
    Harris A
    Br Med Bull; 1998; 54(1):195-205. PubMed ID: 9604443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [UreI: a Helicobacter pylori protein essential for resistance to acidity and for the early steps of murine gastric mucosa infection].
    Bury-Moné S; Skouloubris S; Labigne A; De Reuse H
    Gastroenterol Clin Biol; 2001; 25(6-7):659-63. PubMed ID: 11673732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein microarray analysis for detection of serum anti-Helicobacter pylori antibodies after eradication therapy: a clinical follow-up.
    Cui M; Wei H; Mu F; Yi G; Fu Y; Yue L
    Hepatogastroenterology; 2015; 62(138):503-6. PubMed ID: 25916090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
    Xin Y; Manson J; Govan L; Harbour R; Bennison J; Watson E; Wu O
    BMC Gastroenterol; 2016 Jul; 16(1):80. PubMed ID: 27460211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periodontal therapy improves gastric Helicobacter pylori eradication.
    Zaric S; Bojic B; Jankovic Lj; Dapcevic B; Popovic B; Cakic S; Milasin J
    J Dent Res; 2009 Oct; 88(10):946-50. PubMed ID: 19783805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Rare Cause of Protein-Losing Gastropathy.
    Sasaki Y; Abe Y; Ueno Y
    Gastroenterology; 2016 May; 150(5):1094-1095. PubMed ID: 27020332
    [No Abstract]   [Full Text] [Related]  

  • 17. Potent gastric acid inhibition in Helicobacter pylori eradication.
    Gisbert JP
    Drugs; 2005; 65 Suppl 1():83-96. PubMed ID: 16335862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.
    Sugimoto M; Yamaoka Y
    Arch Immunol Ther Exp (Warsz); 2009; 57(1):45-56. PubMed ID: 19219527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differences between European guideline and planned S3 guideline of DGVS. Need for Helicobacter pylori eradication to be decided on an individual basis].
    MMW Fortschr Med; 2008 Jun; 150(23):48-9. PubMed ID: 18578071
    [No Abstract]   [Full Text] [Related]  

  • 20. Insight into the inhibitory effects of Zanthoxylum nitidum against Helicobacter pylori urease and jack bean urease: Kinetics and mechanism.
    Lu Q; Li C; Wu G
    J Ethnopharmacol; 2020 Mar; 249():112419. PubMed ID: 31759110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.